NASDAQ:IMRN Immuron (IMRN) Stock Price, News & Analysis $1.09 -0.04 (-3.54%) Closing price 04:00 PM EasternExtended Trading$1.09 0.00 (0.00%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Immuron Stock (NASDAQ:IMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immuron alerts:Sign Up Key Stats Today's Range$1.08▼$1.1350-Day Range$1.06▼$1.8452-Week Range$0.68▼$2.39Volume88,722 shsAverage Volume793,306 shsMarket Capitalization$8.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing orally delivered therapeutics based on highly specific antibodies derived from hyperimmune bovine colostrum. Its approach is designed to target pathogens and disease-related factors within the gastrointestinal tract without requiring systemic absorption. The company’s leading commercial product is Travelan, an oral antibody-based product intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan is marketed in the United States and Australia, where it is available under applicable regulatory approvals and labeling. Immuron has also investigated additional applications for its antibody platform, including candidates aimed at gastrointestinal infections and inflammatory or metabolic disorders. Immuron is headquartered in Melbourne, Australia, and has historically conducted research, clinical development and commercialization activities in Australia and the United States. Its development programs have included IMM-124E and IMM-529, which have been studied for potential uses in conditions such as nonalcoholic steatohepatitis and Clostridioides difficile infection. The company’s activities and leadership may change as its clinical and commercial programs develop.AI Generated. May Contain Errors. Read More Immuron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreIMRN MarketRank™: Immuron scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingImmuron has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuron has only been the subject of 1 research reports in the past 90 days.Read more about Immuron's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioImmuron has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.54% of the float of Immuron has been sold short.Short Interest Ratio / Days to CoverImmuron has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immuron has recently increased by 240.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuron does not currently pay a dividend.Dividend GrowthImmuron does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Immuron this week, compared to 1 article on an average week.Search Interest5 people have searched for IMRN on MarketBeat in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immuron insiders have not sold or bought any company stock.Percentage Held by Insiders7.01% of the stock of Immuron is held by insiders.Percentage Held by Institutions0.12% of the stock of Immuron is held by institutions.Read more about Immuron's insider trading history. Receive IMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuron and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMRN Stock News HeadlinesImmuron Ltd ADR (IMRN)September 26, 2026 | investing.comImmuron Releases Comprehensive 2026 Annual ReportSeptember 24, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 2 at 1:00 AM | Porter & Company (Ad)Immuron Files 2026 Corporate Governance Statement with ASXSeptember 24, 2026 | tipranks.comImmuron Showcases Oral Antibody Platform at Coffee Microcaps ConferenceSeptember 21, 2026 | tipranks.comImmuron Ltd ADR IMRNSeptember 9, 2026 | morningstar.comM3 Penny Stocks to Watch Today, September 8September 8, 2026 | tipranks.comImmuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBSSeptember 4, 2026 | finance.yahoo.comSee More Headlines IMRN Stock Analysis - Frequently Asked Questions How have IMRN shares performed this year? Immuron's stock was trading at $0.7680 at the beginning of the year. Since then, IMRN stock has increased by 41.9% and is now trading at $1.09. How were Immuron's earnings last quarter? Immuron (NASDAQ:IMRN) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.08) earnings per share for the quarter. The firm earned $1.27 million during the quarter. When did Immuron IPO? Immuron (IMRN) raised $6 million in an IPO on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager. How do I buy shares of Immuron? Shares of IMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuron investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX). Company Calendar Last Earnings8/14/2026Today10/02/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IMRN's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMRN CIK1660046 Webwww.immuron.com.au Phone(138) 892-4854Fax6103 98227735Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.26 Quick Ratio5.98 Sales & Book Value Annual Sales$5.47 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book1.16Miscellaneous Outstanding Shares8,070,000Free Float7,505,000Market Cap$8.80 million OptionableNot Optionable Beta1.09 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:IMRN) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
